BioNTech and DualityBio Reveal Promising Treatment for Advanced Endometrial Cancer
Mainz, Saturday 11 April 2026
BioNTech’s targeted therapy achieved an impressive 48% response rate in advanced endometrial cancer patients, marking a significant clinical breakthrough that prompts a planned 2026 regulatory filing.
Clinical Efficacy and Trial Mechanics
On 11 April 2026, the Society of Gynecologic Oncology (SGO) annual meeting in San Juan, Puerto Rico, served as the platform for a pivotal data presentation [2]. BioNTech SE and its partner Duality Biologics unveiled the primary analysis from their Phase 2 clinical cohort evaluating trastuzumab pamirtecan, scientifically designated as BNT323/DB-1303 [1][2]. The data represents the largest study to date reporting outcomes for an anti-HER2 antibody-drug conjugate (ADC) specifically targeting advanced endometrial cancer [2]. The trial enrolled 145 patients whose disease had progressed following first-line chemotherapy, offering a critical lifeline to a demographic with historically limited therapeutic options [1][2].
Safety Profile and Treatment Tolerability
While the efficacy data points toward a substantial clinical breakthrough, evaluating the safety profile is equally critical for any oncology asset transitioning from the laboratory to the market. In the 145-patient expansion cohort, treatment-related adverse events of grade 3 or higher were reported in 68 individuals, representing 46.9% of the trial population [1]. A specific point of clinical monitoring for ADCs is the risk of interstitial lung disease or pneumonitis; in this cohort, adjudicated cases of grade 3 or higher occurred in 4.8% of the participants [1].
Regulatory Milestones and Commercial Trajectory
The pathway to commercialisation for trastuzumab pamirtecan is accelerating, supported by previously established regulatory frameworks. In 2023, the United States Food and Drug Administration (FDA) granted both Fast Track and Breakthrough Therapy designations for the candidate in the treatment of endometrial cancer [1][2]. Leveraging this momentum, BioNTech and DualityBio are actively preparing to file a Biologics License Application (BLA) later in 2026, though this timeline remains contingent upon forthcoming regulatory feedback [alert! ‘BLA filing in 2026 is planned but strictly subject to ongoing regulatory feedback from the FDA’] [1][2].
Strategic Evolution in the Oncology Landscape
For BioNTech, originally renowned for its pioneering mRNA vaccine technology, these latest developments signify a robust diversification into targeted oncology [GPT]. Professor Dr Özlem Türeci, Chief Medical Officer and co-founder of BioNTech, reiterated that HER2 remains a central therapeutic target, particularly in gynaecological and breast cancers [2]. By advancing trastuzumab pamirtecan as both a monotherapy and in innovative combination approaches, the company is aggressively pursuing a leading position in the competitive ADC market [2].